Hughes, Timothy P., Branford, Susan, Cooney, Julian, Leahy, Michael F., Rowlings, Philip, Catalano, John, Hertzberg, Mark, Filshie, Robin, Mills, Anthony K., Fay, Keith, Durrant, Simon, Januszewicz, Henry, White, Deborah L., Joske, David, Underhill, Craig, Dunkley, Scott, Lynch, Kevin, Grigg, Andrew, Reynolds, John, Koelmeyer, Rachel, Seymour, John F., Taylor, Kerry, Arthur, Chris, Schwarer, Anthony K., Morton, James. American Society of Hematology; 2008. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.

Joshi, Maansi, Taper, John, Huang, Gillian, Hertzberg, Mark, Forsyth, Cecily, Rowlings, Philip, Campbell, Philip, Crispin, Philip, Harvey, Michael, Underhill, Craig, Bayley, Angela, Byth, Karen. Taylor & Francis; 2020. Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation.

Glewis, Sarah, Krishnasamy, Mei, Campbell, Ian, Martin, Jennifer H., Tie, Jeanne, Alexander, Marliese, Michael, Michael, Lingaratnam, Senthil, Harris, Sam, Underhill, Craig, Georgiou, Chloe, Warren, Mark, Campbell, Robert, IJzerman, Maarten, Fagery, Mussab. Wiley-Blackwell; 2023. Patient and health care professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: a cross sectional survey..